Login / Signup

Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.

Nicolas Barry DelongchampsAlexandre SchullJulien AnractJean-Paul AbecassisMarc ZerbibMathilde SibonyLéa JiletHendy AbdoulVincent GoffinMichaël Peyromaure
Published in: PloS one (2021)
OBT-fusion targeted FMA was feasible, precise, and safe in patients with low to intermediate risk localized prostate cancer.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • cancer therapy
  • clinical trial
  • study protocol
  • radiofrequency ablation
  • randomized controlled trial
  • drug delivery
  • phase iii